Cargando…
Tyrosine kinase gene fusions in cancer: translating mechanisms into targeted therapies
Tyrosine kinase fusion genes represent an important class of oncogenes associated with leukaemia and solid tumours. They are produced by translocations and other chromosomal rearrangements of a subset of tyrosine kinase genes, including ABL, PDGFRA, PDGFRB, FGFR1, SYK, RET, JAK2 and ALK. Based on re...
Autores principales: | Medves, Sandrine, Demoulin, Jean-Baptiste |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3823288/ https://www.ncbi.nlm.nih.gov/pubmed/21854543 http://dx.doi.org/10.1111/j.1582-4934.2011.01415.x |
Ejemplares similares
-
Review of current classification, molecular alterations, and tyrosine kinase inhibitor therapies in myeloproliferative disorders with hypereosinophilia
por: Havelange, Violaine, et al.
Publicado: (2013) -
Receptor Tyrosine Kinase-Targeted Cancer Therapy
por: Yamaoka, Toshimitsu, et al.
Publicado: (2018) -
Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy
por: Sierra, J Rafael, et al.
Publicado: (2010) -
ALK: a tyrosine kinase target for cancer therapy
por: Holla, Vijaykumar R., et al.
Publicado: (2017) -
Tyrosine Kinase Inhibitors in Cancer: Breakthrough and Challenges of Targeted Therapy
por: Pottier, Charles, et al.
Publicado: (2020)